Recombinant human inosine monophosphate dehydrogenase type I and type II proteins: Purification and characterization of inhibitor binding
- 11 May 1995
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 49 (9) , 1323-1329
- https://doi.org/10.1016/0006-2952(95)00026-v
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Probing the Active Site of Human IMP Dehydrogenase Using Halogenated Purine Riboside 5'-Monophosphates and Covalent Modification ReagentsBiochemistry, 1994
- Human IMP Dehydrogenase Catalyzes the Dehalogenation of 2-Fluoro- and 2-Chloroinosine 5'-Monophosphate in the Absence of NADBiochemistry, 1994
- Atomic Structure of Adenosine Deaminase Complexed with a Transition-State Analog: Understanding Catalysis and Immunodeficiency MutationsScience, 1991
- Mycophenolic acid and thiazole adenine dinucleotide inhibition of Tritrichomonas foetus inosine 5'-monophosphate dehydrogenase: implications on enzyme mechanismBiochemistry, 1990
- Dual inhibitory effect of bredininCell Biochemistry and Function, 1989
- Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenaseBiochemistry, 1988
- Purification of IMP dehydrogenase from rat hepatoma 3924ALife Sciences, 1987
- Thiazole-4-carboxamide adenine dinucleotide (TAD). Analogs stable to phosphodiesterase hydrolysisJournal of Medicinal Chemistry, 1986
- Inosine 5′-monophosphate dehydrogenase from Sarcoma 180 cells—Substrate and inhibitor specificityBiochemical Pharmacology, 1976
- Tight-binding inhibitors—IBiochemical Pharmacology, 1975